Legend Biotech Corp
Legend Biotech develops CAR-T cell therapies, including CARVYKTI for relapsed or refractory multiple myeloma, which it markets with Johnson & Johnson.
424B4Sep 28Latest SEC filing
Sep 24Latest story
Sign inSign inLegend Biotech develops CAR-T cell therapies, including CARVYKTI for relapsed or refractory multiple myeloma, which it markets with Johnson & Johnson.